Quality of life in patients with toenail onychomycosis

Mycoses

Volumn 56, Issue 5, 2013, Pages 543-551

  Milobratović, Danica ^a   Janković, Slavenka ^b   Vukičević, Jelica ^b,c   Marinković, Jelena ^b   Janković, Janko ^b   Railić, Zoran ^c  

^a Military Medical Centre   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Dermatology; ONYCHO; Onychomycosis; Quality of life; SF 36

Indexed keywords

ADULT; AGED; ARTICLE; BLUE COLLAR WORKER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TOENAIL ONYCHOMYCOSIS;

DERMATOLOGY; ONYCHO; ONYCHOMYCOSIS; QUALITY OF LIFE; SF-36;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NAILS; ONYCHOMYCOSIS; QUALITY OF LIFE; QUESTIONNAIRES; YOUNG ADULT;

EID: 84881029684     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12072     Document Type: Article

References (32)

1. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol 2003; 149: 1-4.
2. Gill D, Marks R. A review of the epidemiology of tinea unguium in the community. Austral J Dermatol 1999; 40: 6-13.
3. Ghannoum MA, Hajjeh RA, Scher R et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-8.
4. Sigurgeirsson B, Steingrimsson Ó. Risk factors associated with onychomycosis. J Europ Acad Dermatol Venerol 2004; 18: 48-51.
5. Drake LA, Scher RK, Smith EB et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702-4.
6. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41: 189-96.
7. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11: 193-205.
8. Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998; 38: 64-68.
9. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35: 2-5.
10. Warshaw EM, Foster JK, Cham PM, Grill JP, Chen SC. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007; 46: 1279-86.
11. Turner RR, Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000; 9: 39-53.
12. Szepietowski JC, Reich A, Pacan P et al. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Europ Acad Dermatol Venerol 2007; 21: 491-6.
13. Reich A, Szepietowski JC. Health-related quality of life in patients with nail disorders. Am J Clin Dermatol 2011; 12: 313-20.
14. Saunte DML, Holgersen JB, Hedersdal M et al. Prevalence of toenail onychomycosis in diabetic patients. Acta Derm Venereol 2006; 86: 425-8.
15. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
16. Ware JE. SF-36 Health Survey update. Spine 2000; 25: 3130-9.
17. ProQuolid Patient-Reported Outcome and Quality of Life Instruments Database SF-36 Health Survey Serbian version. URL http://www.proquolid.org/ [accessed on 20 June 2012].
18. Maslic SD, Vuletic G. Psychometric evaluation and establishing norms of Croatian SF-36 Health Survey: framework for subjective health research. Croat Med J 2006; 47: 95-102.
19. Aaronson NK, Muller M, Cohen PD et al. Translation, validation and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055-68.
20. Lubeck DP, Gause D, Schein JR, Prebil LE, Potter LP. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999; 18: 121-9.
21. Shaw JW, Joish VN, Coons SJ. Onychomycosis health-related quality of life considerations. Pharmacoeconomics 2002; 20: 23-36.
22. Tabolli S, Alessandroni L, Gaido J, Sampogna F, Di Pietro C, Abeni D. Health-related quality of life and nail disorders. Acta Derm Venereol 2007; 87: 255-9.
23. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22: 87-89.
24. Lubeck DP, Patrick DL, McNulty P, Fifer SK, Birnabum J. Quality of life of persons with onychomycosis. Qual Life Res 1993; 2: 341-8.
25. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36: 754-6.
26. Kowalczuk-Zieleniec E, Nowicki E, Majkowicz M. Onychomycosis changes quality of life. J Eur Acad Dermatol Venerol 2002; 16(Suppl. 1):248 (P23-20).
27. Kaplan MS, Huguet N, Feeny D et al. Alcohol use patterns and trajectories of health-related quality of life in middle-aged and older adults: a 14-year population-based study. J Stud Alcohol Drugs 2012; 73: 581-90.
28. Myint PK, Smith RD, Luben RN et al. Lifestyle behaviours and quality-adjusted life years in middle and older age. Age Ageing 2011; 40: 589-95.
29. Poikolainen K, Vartiainen E, Korhonen HJ. Alcohol intake and subjective health. Am J Epidemiol 1996; 144: 346-50.
30. Ferreira MP, Weems MKS. Alcohol consumption by aging adults in the United States: health benefits and detriments. J Am Diet Assoc 2008; 108: 1668-76.
31. Lu Y, Duller P, Van der Valk PGM, Evers AWM. Helplessness as predictor of stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom 2003; 4: 146-50.
32. Sampogna F, Piccardi A, Chren MM et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosomatic Med 2004; 66: 620-4.